NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, News & Analysis

$9.52
-0.13 (-1.35 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$9.41
Now: $9.52
$9.70
50-Day Range
$8.59
MA: $9.40
$10.85
52-Week Range
$8.40
Now: $9.52
$19.36
Volume2.00 million shs
Average Volume1.61 million shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$346.64 million
Book Value($1.27) per share

Profitability

Net Income$-282,370,000.00

Miscellaneous

Employees515
Market Cap$1.49 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.


Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced its quarterly earnings data on Tuesday, July, 30th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.15. The biotechnology company earned $102.22 million during the quarter, compared to the consensus estimate of $89.28 million. The company's revenue was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.

What price target have analysts set for IRWD?

11 brokerages have issued 1 year price objectives for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $15.05 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

Media headlines about IRWD stock have been trending negative on Tuesday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
  • Mr. Thomas A. McCourt, Pres (Age 62)
  • Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
  • Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.97%), Brown Capital Management LLC (7.88%), Janus Henderson Group PLC (4.85%), Janus Henderson Group PLC (4.85%), EcoR1 Capital LLC (2.99%) and Westfield Capital Management Co. LP (1.53%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Which major investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Canada Pension Plan Investment Board, D. E. Shaw & Co. Inc., Morgan Stanley, Cubist Systematic Strategies LLC, Marshall Wace LLP, BNP Paribas Arbitrage SA and NumerixS Investment Technologies Inc. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Which major investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was acquired by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, Peregrine Capital Management LLC, Nuveen Asset Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Vanguard Group Inc., Westfield Capital Management Co. LP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $9.52.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $1.49 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  532 (Vote Underperform)
Total Votes:  966
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: CD Ladder

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel